News

A new fluorescent imaging probe can for the first time objectively and non-invasively measure loss of smell, clinically known as anosmia.

SNMMI releases the 2024 Annual Meeting Awards Guide

A newly developed imaging method, granzyme B PET, can non-invasively detect inflammatory bowel disease (IBD) and provide a real-time picture of active inflammation in the tissue, according to new research published in the July issue of JNM.

On Tuesday, July 9, the Centers for Medicare & Medicaid Services (CMS) released the proposed rule for the 2025 Medicare Physician Fee Schedule (MPFS). Below are key takeaways SNMMI would like to make our members aware of.

Over the past year or two, you might have noticed an uptick in the use of 99mTc-pyrophosphate (PYP) scans to diagnose cardiac amyloidosis. This trend prompts several questions: Why the renewed interest in a condition once considered rare? What is dri

Toronto, Ontario—The SNMMI Mars Shot Research Fund is excited to announce that Jason S. Lewis, PhD, EmilyTow Chair in Oncology, vice chair for Research in the Department of Radiology, and chief of the Radiochemistry and Imaging Sciences Service at Me

Reston, VA—Extended prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy (177Lu-PSMA) beyond six cycles is an effective and well-tolerated treatment for metastatic castration-resistant prostate cancer patients, according to

A comparative analysis between FAPI and 18F-FDG PET/CT for the systemic staging of newly diagnosed breast cancer shows that FAPI PET/CT is more accurate in staging patients. Nearly 20 percent of patients were restaged by FAPI PET/CT, indicating the r

Combination of alpha- and beta-radionuclide therapy is feasible, tolerable, and effective for colorectal cancer, according to preclinical research presented at the 2024 Society of Nuclear Medicine and Molecular Imaging Annual meeting. This new approa

A newly developed radiotracer can generate high quality and readily interpretable images of cardiac amyloidosis, a condition referred to as the “Alzheimer’s disease of the heart.” As the first amyloid-specific and pan-amyloid binding radiotracer desi